LARAMED: A Laboratory for Radioisotopes of Medical Interest

The widespread availability of novel radioactive isotopes showing nuclear characteristics suitable for diagnostic and therapeutic applications in nuclear medicine (NM) has experienced a great development in the last years, particularly as a result of key advancements of cyclotron-based radioisotope production technologies. At Legnaro National Laboratories of the National Institute of Nuclear Physics (LNL-INFN), Italy, a 70-MeV high current cyclotron has been recently installed. This cyclotron will be dedicated not only to pursuing fundamental nuclear physics studies, but also to research related to other scientific fields with an emphasis on medical applications. LARAMED project was established a few years ago at LNL-INFN as a new research line aimed at exploiting the scientific power of nuclear physics for developing innovative applications to medicine. The goal of this program is to elect LNL as a worldwide recognized hub for the development of production methods of novel medical radionuclides, still unavailable for the scientific and clinical community. Although the research facility is yet to become fully operative, the LARAMED team has already started working on the cyclotron production of conventional medical radionuclides, such as Tc-99m, and on emerging radionuclides of high potential medical interest, such as Cu-67, Sc-47, and Mn-52.

[1]  P. Garvey,et al.  Accelertor breeder target neutronics: AECL's underlying research program. [Atomic Energy of Canada Limited (AECL)] , 1978 .

[2]  I. Sugai.  An application of a new type deposition method to nuclear target preparation , 1997 .

[3]  A. Celler,et al.  Implementation of Multi-Curie Production of 99mTc by Conventional Medical Cyclotrons , 2014, The Journal of Nuclear Medicine.

[4]  P. Martini,et al.  Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons , 2017, Drug development and industrial pharmacy.

[5]  S. Qaim.  The present and future of medical radionuclide production , 2012 .

[6]  A. Duatti,et al.  Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P. , 2014, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  A. Corazza,et al.  In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals. , 2018, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  A. Duatti,et al.  14 MeV Neutrons for 99Mo/99mTc Production: Experiments, Simulations and Perspectives , 2018, Molecules.

[9]  M. Gambaccini,et al.  Accelerator-based production of 99Mo: a comparison between the 100Mo(p,x) and 96Zr(α,n) reactions , 2015, Journal of Radioanalytical and Nuclear Chemistry.

[10]  D. Campo,et al.  SPES: A new cyclotron-based facility for research and applications with high-intensity beams , 2017 .

[11]  L. Metello.  99mTc-Technetium Shortage: Old Problems Asking for New Solutions. , 2015, Journal of medical imaging and radiation sciences.

[12]  V. Palmieri,et al.  Innovative Target for Production of Technetium-99m by Biomedical Cyclotron , 2018, Molecules.

[13]  A. Duatti,et al.  Design and Synthesis of 99mTcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection , 2018, Pharmaceuticals.

[14]  A. Taibi,et al.  Evaluation of 99 Mo and 99 m Tc Productions Based on a High-Performance Cyclotron , 2015 .

[15]  P. Martini,et al.  Radiochemical purity and stability of 99mTc-HMPAO in routine preparations , 2017, Journal of Radioanalytical and Nuclear Chemistry.

[16]  A. Duatti,et al.  Influence of the Generator in-Growth Time on the Final Radiochemical Purity and Stability of Radiopharmaceuticals , 2013 .

[17]  A. Rosato,et al.  Radioisotopic purity and imaging properties of cyclotron-produced 99mTc using direct 100Mo(p,2n) reaction , 2018, Physics in medicine and biology.

[18]  G. Vecchi,et al.  Evaluation of and Productions Based on a High-Performance Cyclotron , 2013 .

[19]  G. Meinken,et al.  Development of a large scale production of 67Cu from 68Zn at the high energy proton accelerator: closing the 68Zn cycle. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[20]  A. Dash,et al.  Sustained Availability of 99mTc: Possible Paths Forward , 2013, The Journal of Nuclear Medicine.

[21]  A. Koning,et al.  The options for the future production of the medical isotope 99Mo , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  A. Celler,et al.  Direct Production of 99mTc via 100Mo(p,2n) on Small Medical Cyclotrons☆ , 2015 .

[23]  A. Duatti,et al.  The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. , 2018, Drug discovery today.

[24]  A. Duatti,et al.  A solvent-extraction module for cyclotron production of high-purity technetium-99m. , 2016, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[25]  M. Giganti,et al.  Influence of Storage Temperature on Radiochemical Purity of 99mTc-Radiopharmaceuticals , 2018, Molecules.

[26]  Luis Martí-Bonmatí,et al.  Multimodality imaging techniques. , 2010, Contrast media & molecular imaging.

[27]  M. Gambaccini,et al.  Experimental cross section evaluation for innovative 99Mo production via the (α,n) reaction on 96Zr target , 2014, Journal of Radioanalytical and Nuclear Chemistry.

[28]  U. Holzwarth,et al.  The excitation functions of (100)Mo(p,x)(99)Mo and (100)Mo(p,2n)(99m)Tc. , 2014, Applied Radiation and Isotopes.